We work with our members, the Government, NICE, the NHS and other stakeholders to ensure that the full value of medicines is understood and assessed appropriately, and that patients and the NHS can access the medicines they need when they need them.
Cancer Drugs FundThe Commercial Team is working closely with a range of our member companies on the future of the Cancer Drugs Fund and the design of value based pricing.
Health Technology AssessmentThe commercial team is responsible for supporting our HTA Taskforce which is made up of senior representatives from member companies.
QIPP and Joint WorkingFind out about Quality, Innovation, Productivity and Prevention (QIPP) and how the NHS is improving the quality of care it delivers.
Working with the NHSWe are committed to working together with UK Government and the NHS.
Partnership groupsWe take part a number of active groups looking at a diverse range of therapy area topics.
A joint investment in the development of a common database for new medicines which will be used by NHS horizon scanning organisations to support better financial and service planning for the introduction of medicines into the NHS.
Accelerated Access Review (AAR)
The Accelerated Access Review (AAR) officially launched in March 2015. The Review will make recommendations to Government on reforms to accelerate access for NHS patients to innovative medicines and medical technologies.